Tango Therapeutics (TNGX) News Today $1.46 -0.01 (-0.68%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Trv Gp Vi LLC Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)Trv Gp Vi LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 194,174 shares of the company's sApril 22 at 6:54 AM | marketbeat.comGilead Sciences Inc. Acquires Shares of 4,854,443 Tango Therapeutics, Inc. (NASDAQ:TNGX)Gilead Sciences Inc. bought a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,854,443 shares of the company's stock, valued at approximatelyApril 20, 2025 | marketbeat.comBrokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33April 19, 2025 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for TNGXTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Tango Therapeutics in a research report issued on Monday, April 14th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.35) per share for theApril 18, 2025 | marketbeat.comQ1 EPS Forecast for Tango Therapeutics Reduced by AnalystApril 18, 2025 | americanbankingnews.comQ1 Earnings Forecast for TNGX Issued By HC WainwrightTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, April 14th. HC Wainwright analyst R. Burns forecasts that the companyApril 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TNGX Q1 Earnings?April 17, 2025 | americanbankingnews.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from AnalystsTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price target amonApril 16, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Tango Therapeutics (NASDAQ:TNGX)HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Monday.April 16, 2025 | marketbeat.comBarbara Weber, M.D., Elected to ITM Supervisory BoardApril 9, 2025 | markets.businessinsider.comSchroder Investment Management Group Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)Schroder Investment Management Group bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 655,158 shares of the company's stock, valued at aApril 8, 2025 | marketbeat.comShort Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Expands By 29.4%Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 9,110,000 shares, an increase of 29.4% from the February 28th total of 7,040,000 shares. Approximately 15.4% of the shares of the company are sold short. Based on an average daily volume of 873,500 shares, the days-to-cover ratio is presently 10.4 days.April 1, 2025 | marketbeat.comTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comBarclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)March 24, 2025 | markets.businessinsider.comTango Therapeutics, Inc. (NASDAQ:TNGX) Sees Large Growth in Short InterestTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 7,040,000 shares, a growth of 18.5% from the February 13th total of 5,940,000 shares. Approximately 11.9% of the shares of the stock are sold short. Based on an average daily volume of 967,300 shares, the short-interest ratio is currently 7.3 days.March 19, 2025 | marketbeat.comCantor Fitzgerald Has Weak Estimate for TNGX FY2025 EarningsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald analyst E. SchmidMarch 12, 2025 | marketbeat.comTango Therapeutics (TNGX) Expected to Announce Earnings on MondayTango Therapeutics (NASDAQ:TNGX) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comTango Therapeutics (TNGX) Receives a Buy from BarclaysMarch 1, 2025 | markets.businessinsider.comTango Therapeutics (NASDAQ:TNGX) Issues Earnings ResultsTango Therapeutics (NASDAQ:TNGX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.February 28, 2025 | marketbeat.comTango Therapeutics Advances Cancer Treatment PipelineFebruary 28, 2025 | tipranks.comTango Therapeutics sees cash runway into 3Q26February 27, 2025 | markets.businessinsider.comTango Therapeutics reports Q4 EPS (35c), consensus (34c)February 27, 2025 | markets.businessinsider.comTango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business HighlightsFebruary 27, 2025 | globenewswire.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The averagFebruary 23, 2025 | marketbeat.comTango Therapeutics to Present at Three Upcoming Investment Bank ConferencesFebruary 20, 2025 | markets.businessinsider.comShort Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 22.5%Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 5,440,000 shares, a decrease of 22.5% from the January 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 11.0% of the shares of the company are sold short.February 15, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for TNGX Q3 Earnings?Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earFebruary 10, 2025 | marketbeat.comOne Tango Therapeutics Insider Raised Stake By 400% In Previous YearFebruary 8, 2025 | finance.yahoo.comInsider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Sells 4,284 Shares of StockFebruary 7, 2025 | insidertrades.comWhat is Leerink Partnrs' Forecast for TNGX Q1 Earnings?Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tango Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will postFebruary 7, 2025 | marketbeat.comDaniella Beckman Sells 4,284 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) StockTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) CFO Daniella Beckman sold 4,284 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $12,809.16. Following the completion of the transaction, the chief financial officer now owns 154,232 shares in the company, valued at $461,153.68. This represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 6, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $22,221.68 in StockTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 7,432 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $22,221.68. Following the completion of the transaction, the insider now owns 165,061 shares of the company's stock, valued at $493,532.39. This trade represents a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 6, 2025 | marketbeat.comTango Therapeutics CFO Beckman sells $25,281 in stockFebruary 6, 2025 | msn.comTango Therapeutics executive sells shares worth $43,865February 6, 2025 | msn.comTango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 SharesTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) CEO Barbara Weber sold 9,778 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares of the company's stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.February 6, 2025 | marketbeat.comTango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology ConferenceJanuary 30, 2025 | globenewswire.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from BrokeragesShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-monJanuary 29, 2025 | marketbeat.comTango Therapeutics: Chance For A Short SqueezeJanuary 23, 2025 | seekingalpha.comAnalysts Set Expectations for TNGX FY2025 EarningsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that theJanuary 22, 2025 | marketbeat.comState Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)State Street Corp raised its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 26.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 2,318,208 shares of the company's stock after purchasing an additional 489,949 shares during the pDecember 24, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by BrokeragesShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price objDecember 10, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest UpdateTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 7,110,000 shares, a decrease of 21.7% from the October 31st total of 9,080,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is presently 3.9 days. Approximately 14.4% of the company's stock are short sold.November 29, 2024 | marketbeat.comTango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | businesswire.comTango Therapeutics, Inc. (NASDAQ:TNGX) Director Purchases $36,200.00 in StockNovember 19, 2024 | insidertrades.comTrv Gp Iv LLC Has $129.82 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)Trv Gp Iv LLC lessened its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,859,075 shares of the company's stock after selling 2,342,400 shares duriNovember 17, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from AnalystsShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have earned an average rating of "Buy" from the eight research firms that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among broNovember 15, 2024 | marketbeat.comB. Riley Boosts Earnings Estimates for Tango TherapeuticsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at B. Riley upped their FY2024 earnings per share estimates for shares of Tango Therapeutics in a research report issued on Monday, November 11th. B. Riley analyst Y. Zhi now forecasts that the company will earn ($1.21) per share forNovember 14, 2024 | marketbeat.comTango Therapeutics price target lowered to $8 from $16 at B. RileyNovember 11, 2024 | markets.businessinsider.comB. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00B. Riley dropped their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a "buy" rating for the company in a research report on Monday.November 11, 2024 | marketbeat.comFY2024 Earnings Forecast for TNGX Issued By Leerink PartnrsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Tango Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst A. Berens now expects that the comNovember 11, 2024 | marketbeat.com Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Media Mentions By Week TNGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNGX News Sentiment▼0.770.73▲Average Medical News Sentiment TNGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNGX Articles This Week▼63▲TNGX Articles Average Week Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies REPL News Today TRVI News Today VALN News Today ORGO News Today ANAB News Today PHAR News Today PRTA News Today OPT News Today COGT News Today KROS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNGX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TNGX Stock Free TNGX Stock Alerts